Featured Research

from universities, journals, and other organizations

China halves tuberculosis prevalence in just 20 years

Date:
March 17, 2014
Source:
The Lancet
Summary:
Over the last 20 years, China has more than halved its tuberculosis (TB) prevalence, with rates falling from 170 to 59 per 100,000 population. This unrivalled success has been driven by a massive scale-up of the directly observed, short-course (DOTS) strategy, from half the population in the 1990s to the entire country after 2000, according to findings from a 20-year-long analysis of national survey data.

Over the last 20 years, China has more than halved its tuberculosis (TB) prevalence, with rates falling from 170 to 59 per 100,000 population. This unrivalled success has been driven by a massive scale-up of the directly observed, short-course (DOTS) strategy, from half the population in the 1990s to the entire country after 2000, according to findings from a 20-year-long analysis of national survey data, published in The Lancet.

"One of the key global TB targets set by the Stop TB Partnership aims to reduce tuberculosis prevalence by 50% between 1990 and 2015. This study in China is the first to show the feasibility of achieving such a target, and China achieved this 5 years earlier than the target date," says study leader Dr Yu Wang from the Chinese Center for Disease Control and Prevention in Beijing, China.

"Huge improvements in TB treatment, driven by a major shift in treatment from hospitals to local public health centres implementing the DOTS strategy, were largely responsible for this success."

China is a major contributor to the TB pandemic, with 1 million new TB cases every year, accounting for 11% of all new cases globally. Two national surveys of tuberculosis prevalence in 1990 and 2000 showed that levels of TB were reduced by around 30% in the 13 provinces where the DOTS program was adopted. However, national TB prevalence fell by just 19% over the decade.

Another survey was done in 2010 to re-evaluate the national TB burden, providing an opportunity to assess the effect of the nationwide expansion of the DOTS program. Nearly 253,000 individuals aged 15 years and older were surveyed in 2010 at 176 investigation points chosen from all 31 mainland provinces. The results show that between 2000 and 2010, national TB prevalence fell by 57% -- tripling the reduction of the previous decade.

During this time, 87% of the total decrease in prevalence was among cases already diagnosed with TB before the survey. The increase of known TB cases treated using DOTS rose from 15% in 2000 to 66% in 2010, and contributed to lower proportions of treatment default (from 43% to 22%) and retreatment (from 84% to 31%).

According to the authors, "The DOTS program has been much more effective in reducing the prevalence of tuberculosis in known cases than in new cases. Because the prevalence in known cases is already very low, future reduction in tuberculosis prevalence is likely to slow substantially unless control efforts in addition to the DOTS strategy are implemented, especially in earlier case detection and treatment and use of new instruments."

Writing in a linked Comment, Giovanni Battista, Director of the WHO Collaborating Centre for Tuberculosis and Lung Diseases in Italy, and Giovanni Sotgiu from the University of Sassari-Research in Italy, point out that because many developing countries have already improved TB treatment using the DOTS strategy, "Long-term, rapid reduction in the tuberculosis burden leading to tuberculosis elimination will need additional efforts, including adoption of new instruments in diagnosis (rapid molecular testing for drug-susceptible and drug-resistant tuberculosis) and treatment (new drugs effective against drug-resistant cases), systematic diagnosis and treatment of latent tuberculosis infection, and better access to care by high-risk populations (including free diagnosis and treatment, and social protection mechanisms preventing income loss)."


Story Source:

The above story is based on materials provided by The Lancet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lixia Wang, Hui Zhang, Yunzhou Ruan, Daniel P Chin, Yinyin Xia, Shiming Cheng, Mingting Chen, Yanlin Zhao, Shiwen Jiang, Xin Du, Guangxue He, Jun Li, Shengfen Wang, Wei Chen, Caihong Xu, Fei Huang, Xiaoqiu Liu, Yu Wang. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. The Lancet, March 2014 DOI: 10.1016/S0140-6736(13)62639-2

Cite This Page:

The Lancet. "China halves tuberculosis prevalence in just 20 years." ScienceDaily. ScienceDaily, 17 March 2014. <www.sciencedaily.com/releases/2014/03/140317203646.htm>.
The Lancet. (2014, March 17). China halves tuberculosis prevalence in just 20 years. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/03/140317203646.htm
The Lancet. "China halves tuberculosis prevalence in just 20 years." ScienceDaily. www.sciencedaily.com/releases/2014/03/140317203646.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins